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218a Monday, March 7, 2011resistance is associated with inadequate target inhibition. Here we report our
most recent efforts to create the analytical and chemical tools needed to directly
measure the enzymatic activities of therapeutic targets including protein ki-
nases, lipid-modifying enzymes and the proteasome. Fluorescent reagents are
under development that report the activity of these various enzymes with the
goal of performing biochemical assays in primary cells. The basic design incor-
porates enzyme substrates that are modified to create compounds which can be
loaded into cells where they are modified by the enzyme of interest. Work has
included modification of peptides to confer membrane permeability and to
achieve long intracellular lifetimes. Microelectrophoretic separations com-
bined with low-level fluorescence detection enable the quantitative analysis
of these compounds from single mammalian cells. This capability addresses
three major issues currently faced in the biochemical analysis of clinical sam-
ples: the need for direct measurement of the enzymatic activity of target pro-
teins; sample size requirements that are feasible for clinical implementation;
and sample heterogeneity that can mask pertinent aspects related to therapeutic
response.
1190-Pos Board B100
CDP-Chase, a CDP-Choline Pyrophosphatase, is a Member of a Novel
Nudix Family in Gram-Positive Bacteria
Krisna C. Duong-Ly, Sandra B. Gabelli, WenLian Xu, Christopher A. Dunn,
Maurice J. Bessman, L. Mario Amzel.
A Nudix enzyme from Bacillus cereus, CDP-Chase, acts as a CDP-choline
pyrophosphatase, hydrolyzing the phosphoanhydride bond of CDP-choline
to produce CMP and phosphocholine. The structure of the free enzyme, de-
termined to 1.8 A˚ resolution, shows that the enzyme is an asymmetric dimer.
Each monomer consists of two domains, an N-terminal helical domain and
a C-terminal Nudix domain. The N-terminal domain is placed relative to
the C-terminal domain in such a way that produces an overall asymmetry.
Residues that may be important for determining the asymmetry are conserved
among a group of uncharacterized Nudix enzymes from Gram-positive bac-
teria. In addition to its Nudix activity, the enzyme has a 3’ to 5’ RNA exo-
nuclease activity. This alternative activity appears to be facilitated by the
asymmetry in the protein as the position of the N-terminal domain results
in differences in the exposure of the two enzyme active sites. Two single-
site mutations, E112A and E163A, were characterized to further investigate
the mechanism of the enzyme. E112 is involved in the coordination of cata-
lytic metals in both active sites, and E163 is only in close proximity in one of
the active sites. Both mutations abolish CDP-choline pyrophosphatase activ-
ity but E112A has a much more profound effect on RNase activity, support-
ing a model where CDP-choline hydrolysis is catalyzed by one active site of
the dimer and RNA exonuclease activity is catalyzed by the other. These data
suggest that CDP-Chase is a member of a novel Nudix family in which struc-
tural asymmetry has a profound effect on the recognition of substrates by the
Nudix enzymatic machinery.
1191-Pos Board B101
Active Sites of Enzymes are Crowded with Charge
David Jimenez-Morales, Jie Liang, Bob Eisenberg.
The chemistry of enzymes occurs at active sites that concentrate biological
function into functional pockets. Functional pockets mix catalytic amino acids
and substrate in tiny volumes. Here, we look for biological properties of that
small space. We imagine that electric charge plays important roles, because
even one charge in a small space produces large electric fields. To estimate den-
sities of fixed charge, we measure the volume of functional pockets and count
‘charged residues’ in it. We collect locations of functional pockets from en-
zymes of known structure that catalyze the main six enzymatic reactions. Func-
tional amino acids are identified by their participation in catalysis. We measure
the volume of pockets using both solvent-accessible and molecular-surface
models. ‘Charged residues’ are R, K and H (positive); E and D (negative).
Charge density is extraordinarily large (~20 Molar on average, often larger).
Mobile counterions for the fixed charge are presumably nearby in high density.
Active sites do not resemble the infinitely dilute ideal solutions of classical en-
zyme kinetics. Their enormous charge density is comparable to the charge den-
sity of solid NaCl. Different types of enzymes have different charge densities.
Hydrolases show the largest values of charge density. Some enzymes have ex-
traordinarily large charge density -phosphoglycerate mutase (PDB = 1o98, den-
sity of charge 104 Molar, Molecular Surface), or sulfurtransferase (PDB =
1e0c, 109 Molar, Molecular Surface). Crowding of charged side-chains and
ions produces enormous steric and electrostatic forces in these tiny active sites.
The balance of these forces seems likely to be of great importance to enzyme
function. Many charged pockets are also found away from active sites. Charged
pockets are likely to be involved in many surface interactions. They may be res-
ervoirs of electromechanical energy that can drive conformational changes.1192-Pos Board B102
Strong Coulomb Interactions Between Internal and Surface Charges in
Proteins
Victor Khangulov, Carlos A. Castaneda, Michael S. Chimenti, Michael
J. Harms, Daniel G. Isom, Jamie L. Schlessman, Bertrand E. Garcia-Moreno.
Internal ionizable groups in proteins are essential for many biological pro-
cesses. The molecular determinants of their pKa values are poorly understood.
To examine this problem, we measured previously the pKa values of Lys, Arg,
Asp and Glu at 25 internal positions in staphylococcal nuclease. The pKa values
are usually shifted substantially (as many as 6 pKa units) in the direction that
favors the neutral state because dehydration experienced by the ionizable
groups in their buried positions is not compensated by interactions with polar
or charged groups. A subset of variants with internal Lys residues showed ev-
idence of interaction of the internal Lys with surface carboxylic groups. Using
NMR spectroscopy and crystallography we have shown that internal Lys resi-
dues can have significant Coulomb interactions with surface Asp and Glu.
Upon ionization the internal Lys residue remains internal and the proteins re-
main fully folded. The interactions between the internal Lys and surface car-
boxylic groups are long range (6.3 A˚ or more between charged atoms) and
are mostly through protein. Long-range pairwise interactions as high as 2
kcal/mol have been measured. In some cases strong effects are governed by
the sum of many weaker long-range interactions that cannot be decomposed ex-
perimentally into pairwise contributions. Overall, there is strong evidence that
surface carboxylic groups stabilize the charged form of many internal Lys res-
idues. The experimentally measured Coulomb interaction energies between in-
ternal and surface charges constitute invaluable constraints for benchmarking
of structure-based electrostatics calculations. They also suggest a strategy for
modifying the pKa value of active site residues by the engineering of surface
charges.
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Enzyme-Triggered Anticancer Lipid Prodrugs
Ahmad Arouri, Palle J. Pedersen, Sidsel K. Adolph, Mogens W. Madsen,
Thomas L. Andresen, Robert Madsen, Mads H. Clausen, Ole G. Mouritsen.
The use of liposomal drug delivery systems for cancer treatment is primarily
hampered by the complications associated with making liposomal encapsula-
tions that are: 1) stable outside the target area and 2) provide efficient drug re-
lease at the target. The escape of encapsulated drugs from the liposomes by
passive diffusion often leads to suboptimal drug concentrations in the cancer
tissues. Hence, we have constructed lipid prodrugs that can form liposomes
and therefore overcome the necessity for liposome drug loading. The prodrugs
were prepared using ether phospholipids esterified in the sn-2 position to anti-
cancer drugs like chlorambucil, retinoic acids or prostaglandin, where the ac-
tive drug can be released at the target tissue by means of secretory
phospholipase A2 (sPLA2), an enzyme that is upregulated in various cancer tis-
sues. In this work, the biophysical characterization, cytotoxicity and enzymatic
hydrolysis of the prodrugs are presented. It is also shown how the mixing of the
prodrugs with sPLA2-cleavable phospholipids was found to enhance the prop-
erties of the liposomal formulation and to strengthen its targeting capacity.
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Inhibitors of Leishmania Major Farnesyl Diphosphate Synthase: Crystal-
lographic and Calorimetric Studies
Srinivas Aripirala, Sandra Gabelli, Eric Oldfield, Dolores
Gonzalez Pacanowska, Mario Amzel.
Leishmaniasis is a parasitic disease predominantly seen in tropical and subtropi-
cal regions. Different Leishmania species are responsible for different forms of
the disease: Viscereal Leishmaniasis, Cutaneous Leishmaniasis and Mucutane-
ous Leishmaniasis. Cutaneous Leishmaniasis, which is caused, by either L. Trop-
icaorL.major affects around1.5millionpeople everyyear. It is transmittedby the
bite of the sandfly, an intermediate host. Rodriguez et. al showed that the bi-
sphosphonates, such as pamidronate inhibit the growth of lesions in mice when
administered intraperitoneally. BPs target the Farnesyl Diphosphate synthase
(FPPS), an enzyme of themevalonate pathway in both parasite and humans, . Ki-
netic studies on LmFPPS showed that the Km for DMAPP is 53 mM. Inhibition
cell based studies against intracellular L. donovani amastigotes show that the
IC50 values for 1-(2-Hydroxy-2,2-bis-phosphono-ethyl) 3-phenyl-pyridinium
Monday, March 7, 2011 219a(300B) and1-(2,2-Bis-phosphono-ethyl)-3-butyl-pyridinium (476A) are 4.68mM
and 6.48 mM respectively. Isothermal Calorimetric studies with these inhibitors
revealed that the binding is entropically driven. X-ray crystallographic structures
of the LmFPPS in complex with 300B, Isopentenyl Pyrophosphate (IPP), and 3
divalent cations and the other in complex with 476A, IPP and 3 divalent cations
were determined.Comparison of these structureswith thoseof the humanenzyme
complexedwith zolendronate reveals significant differences in residues at thebot-
tom of the pocket, such as Glu97 and Leu129, that could be used to tailor speci-
ficity of the bisphosphonates to the parasitic enzyme.
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Computational Enzyme Design: Refining Artificial Enzymes and Explor-
ing Paths of Directed Evolution
Maria P. Frushicheva, Arieh Warshel.
A fundamental challenge in biotechnology and in biochemistry is the ability to
design effective enzymes. In fact, it would be one of the most convincing in-
dications of a full understanding of the origin of enzyme catalysis. Despite
a gradual progress on this front, most of the advances have been made by plac-
ing the reacting fragments in the proper places rather than by optimizing the
environment preorganization, which is the key factor in enzyme catalysis
(Chem. Rev. 2006, 106, 3210-3235). Improving the preorganization and as-
sessing the effectiveness of different design options requires the ability to cal-
culate the actual catalytic effect. Our studies are based on using the empirical
valence bond (EVB) as the main screening tool (for e.g., Biochemistry 2009,
48, 3046-3056). At present this approach appears to provide the most reliable
way for quantifying catalytic effects. Previously, we explored the challenges of
the rational enzyme design in artificial Kemp eliminases with glutamate as
a base (Frushicheva et al., PNAS, Sept 09 2010). It has been shown that due
to the small change in substrate charges upon reaching the transition state
makes it hard to exploit the active site polarity. This appears to be the case
even with the ability to quantify the effect of different mutations. Thus we
study the catalytic effect of the Kemp elimination reaction with different cat-
alytic bases, such as histidine and lysine. This allowed us to exploit change in
basicity as well the larger dipole of the transition charge distribution. We also
investigate the effect of mutations that convert the highly catalytic phospho-
triestrase to a lactonase. Overall we are able to illustrate the effectiveness of
the EVB as a powerful approach for a quantitative screening in rational en-
zyme design.
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Mechanical Tuning of a Catalytic Cystein PKA in Thioredoxin
Pallav Kosuri, Bo Chen, Arne Holmgren, Julio M. Ferna´ndez.
Protein function is often modulated by the protonation state of functional
groups. Thioredoxin is a universally conserved disulfide reductase with wide
substrate specificity, and its catalytic activity is dependent on the deprotonation
of Cys32. This cysteine exhibits a pKa that is markedly lower than free cysteine,
ensuring catalytic activity at physiological pH. Various electrostatic effects
within the active site have been suggested to cause this pKa depression. How-
ever, a consensus on the actual pKa value is still lacking, as reported values
have differed depending on the method used. We show here that the pKa of
Cys32 in human thioredoxin can be modulated by its substrate. We used an
atomic force microscope to detect single disulfide cleavage events in immuno-
globulin substrate proteins. Integrating the data from many such events for
a range of pH conditions enabled precise measurement of the rate of nucleo-
philic attack by thioredoxin, which is linearly dependent on nucleophile con-
centration. Fits to the Henderson-Hasselbalch equation allowed for sensitive
titration of the Cys32 pKa. Interestingly, when altering the mechanical strain
on the substrate we observed a concomitant change in the enzyme pKa. We
could in this manner continuously tune the Cys32 pKa between 6.5 and 7.5.
These results suggest that the conformation of the substrate influences the en-
zyme pKa. Electrostatic interactions in the enzyme-substrate binding interface
could be responsible for this modulation. The substrate dependence of the
Cys32 pKa could explain why previous reports have failed to reach a consensus
on its value. Our findings may indicate a general phenomenon, which brings
into question the relevance of measuring enzyme pKa’s in the absence of phys-
iological substrates.
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Heptosyltransferase I Lipid a Structure Activity Relationships (SAR)
Daniel J. Czyzyk, Erika A. Taylor.
The increasing incidence of antibiotic resistant bacterial infections has neces-
sitated the search for novel targets and mechanisms for therapeutic interven-
tion. Formation of a biofilm enables survival of bacteria in hostile
environments, including in the presence of antimicrobials, thereby prompting
research toward the disruption of bacterial biofilms. Lipopolysaccharide
(LPS), a major constituent of the outer membrane of gram-negative bacteria,plays a key role in the formation and stability of biofilms. Therefore, disrupt-
ing the biosynthesis of the LPS is an attractive mechanism for development
of anti-biofilm agents. One such LPS biosynthetic enzyme is heptosyltrans-
ferase I (Hep I), which is responsible for the transfer of the first L-glyc-
ero-D-manno-heptose to a 3-deoxy-a-D-manno-oct-2-ulopyranosonic acid
(KDO) of the growing Lipid A portion of LPS. Previous attempts to co-crys-
tallize Hep I with both substrates have been unsuccessful, hindering the abil-
ity to effectively visualize the binding interactions important for specificity.
Substrate analogues for E. coli Hep I Lipid A are being used to identify
which portions are necessary and sufficient for binding. Determination of
the SAR of Hep I for these analogues may lead to the discovery of a Lipid
A analogue that is able to be co-crystallized with Hep I. Developing an un-
derstanding of E.coli Hep I binding interactions with lipid A will enhance ef-
forts to develop a Hep I inhibitor and possibly the discovery of a new anti-
biofilm agent.
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Mechanistic Study of Dihydropteridine Reductase (DHPR) Using Raman
Spectroscopy
Soheila Adl.
York College of CUNY, Jamaica, NY, USA.
Dihdyropteridine reductase (DHPR) catalyzes reduction of the unstable quino-
noid dihydropteridine to the active tetrahydropteridine form through the oxida-
tion of NADH. DHPR deficiency or any blockage in biosynthesis of
tetrahydropteridine results in development of phenylketonuria (PKU), a pro-
gressive neurological illness which does not respond to dietary treatment. It
has been speculated that DHPR or metabolites associated with it may have anti-
oxidative properties. In another study, DHPR has been shown to have NADH-
ferric reductase activity. This activity is postulated to have an important role in
dietary iron uptake. There is an emerging role, though mechanistically unclear
at this point, for BH4 in maintaining nitric oxide synthase (NOS) activity. NOS
produces the signaling agent nitric oxide (NO) from L-arginine. In the light of
these emerging roles there is a growing need to completely understand how
DHPR works.
The mechanism of catalysis in DHPR is not fully understood. Previous studies
have suggested the involvement of the thiol group of a cysteine residue in
DHPR. DFT computational modeling of Raman spectra of the unlabeled and
isolabeled inhibitor of DHPR provides valuable information for assigning
Raman marker bands which are involved in enzyme- inhibitor interactions. Us-
ing Raman spectroscopic techniques, the effect of the inhibitors/substrate and/
or cofactor on the protonation state of the thiol group is investigated. Raman
spectroscopy is particularly effective because of a unique peak at ca. 2500
cm-1 due to the S-H stretch and another one at ca. 900 cm-1 due to the C-S
bond. Peak shifts and modulation in intensities are monitored and analyzed
in terms of its mechanistic implications.1199-Pos Board B109
Structural and Functional Studies of a New Isoform of Indoleamine 2, 3-
dioxygenase
Laura B. Granell-Ortiz, Dr. Syun-Ru Yeh.
Indoleamine 2, 3-dioxygenase-1 (IDO1) is a heme-containing enzyme that cat-
alyzes the first and rate-limiting step of the kynurenine (KYN) pathway, the
major catabolic route of L-tryptophan (L-Trp). Expression of IDO1 is induced
by immunological stimuli (e.g. interferon gamma), causing T-cell inhibition.
Therefore, IDO1 has been implicated in various physiological and patho-phys-
iological processes, including viral infections and cancer. In cancer cells, IDO1
is expressed to help tumors evade immune surveillance, resulting in uncon-
trolled tumor growth and cancer progression. The IDO1 inhibitor, 1-methyl-
tryptophan (1MT) has been known to inhibit mouse IDO1 and, together with
chemotherapeutic agents, to reduce tumor size. However, additional tests re-
vealed that the L-isomer of 1-MT has more potent inhibitory efficiency in vitro
with purified IDO1, while the D-isomer is more potent in vivo. The discrepancy
of these results was partially answered by the recent discovery of a new isoform
of IDO1, named IDO2, which have been shown to be preferentially inhibited by
D-1MT in vivo. Although, D-1MT is in phase I clinical trials, no structural or
molecular studies of purified human IDO2 has been reported so far. Hence,
there exists a critical need for the understanding of the structural and functional
properties of IDO2, in order to clarify the physiological functions of IDO2 to
provide guidelines for the development of new and potent drugs for cancer ther-
apy. To obtain a better insight into the structure-function of IDO2 we have
cloned, expressed and purified recombinant human IDO2. Our spectroscopic
and kinetic data provide a glimpse of the structural and functional properties
of IDO2 for the first time, and suggest that the action mechanism of IDO2 is
distinctive from IDO1.
